TrialHaematologica2022

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.

Walter Fiedler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.